The BioHub – The Avetix Podcast – Episode 5 – Paul Peter Tak (youtube.com)
Summary
Dr. Paul Peter Tak, CEO and President of Candel Therapeutics, shares insights into his extensive career trajectory spanning academia, big pharma, biotech, and venture capital. He reflects on groundbreaking immunotherapy projects that shaped his professional journey, particularly the advent of TNF inhibitors in rheumatology and the current transformative potential of viral and multimodal immunotherapies in oncology.
Dr. Tak highlights Candel’s innovative platforms, including clinical trials targeting difficult-to-treat cancers like non-small cell lung cancer, pancreatic cancer, glioblastoma, and early localized prostate cancer, emphasizing their unique viral-based immunotherapy approaches. He illustrates the company’s strategic approach to drug discovery, focusing on human biology, artificial intelligence, and the versatile use of herpes simplex virus vectors to deliver targeted gene therapies.
Despite recent workforce reductions driven by economic challenges, Dr. Tak remains optimistic about Condel’s future, underscoring a rigorous data-driven strategy, strong collaborations with scientific leaders, and a commitment to long-term value creation. He contrasts the agility and pressures of biotech with big pharma, emphasizing Condel’s streamlined governance and culture of innovation.
Finally, he shares personal philosophies on leadership, resilience, and career development, advocating for intuition, collaboration, and maintaining a balance between professional dedication and personal well-being.
